ARWR Stock: Arrowhead Pharmaceuticals, Inc Reaches $6.38 52-Week High

0
364

Levin Capital Strategies Lp increased General Mtrs Co (GM) stake by 1295.13% reported in 2017Q3 SEC filing. Levin Capital Strategies Lp acquired 1.43 million shares as General Mtrs Co (GM)’s stock declined 12.09%. The Levin Capital Strategies Lp holds 1.54 million shares with $62.19M value, up from 110,399 last quarter. General Mtrs Co now has $61.36 billion valuation. The stock decreased 1.52% or $0.6647 during the last trading session, reaching $43.1953. About 6.47 million shares traded. General Motors Company (NYSE:GM) has risen 7.92% since January 19, 2017 and is uptrending. It has underperformed by 8.78% the S&P500.

The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) hit a new 52-week high and has $6.76 target or 6.00% above today’s $6.38 share price. The 5 months bullish chart indicates low risk for the $477.41 million company. The 1-year high was reported on Jan, 19 by Barchart.com. If the $6.76 price target is reached, the company will be worth $28.64 million more. The stock increased 11.54% or $0.66 during the last trading session, reaching $6.38. About 2.87 million shares traded or 104.61% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has declined 67.27% since January 19, 2017 and is downtrending. It has underperformed by 83.97% the S&P500.

Levin Capital Strategies Lp decreased Take (NASDAQ:TTWO) stake by 4,129 shares to 3,425 valued at $350,000 in 2017Q3. It also reduced Banc Of California Inc (NYSE:BANC) stake by 133,332 shares and now owns 13,080 shares. Verifone Sys Inc (NYSE:PAY) was reduced too.

Among 29 analysts covering General Motors Company (NYSE:GM), 16 have Buy rating, 3 Sell and 10 Hold. Therefore 55% are positive. General Motors Company had 83 analyst reports since July 24, 2015 according to SRatingsIntel. Barclays Capital maintained General Motors Company (NYSE:GM) rating on Monday, September 21. Barclays Capital has “Hold” rating and $36 target. As per Friday, July 24, the company rating was upgraded by Credit Suisse. RBC Capital Markets maintained it with “Sector Perform” rating and $30 target in Thursday, February 4 report. UBS maintained the stock with “Buy” rating in Friday, October 2 report. The firm has “Buy” rating given on Monday, October 2 by Citigroup. As per Wednesday, September 2, the company rating was maintained by Citigroup. Jefferies maintained it with “Hold” rating and $40 target in Monday, October 30 report. The firm has “Hold” rating given on Wednesday, October 25 by RBC Capital Markets. CFRA maintained it with “Buy” rating and $51.0 target in Tuesday, January 16 report. The rating was initiated by Morgan Stanley on Wednesday, February 24 with “Underweight”.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.15, from 1.02 in 2017Q2. It fall, as 66 investors sold GM shares while 322 reduced holdings. 96 funds opened positions while 242 raised stakes. 1.01 billion shares or 1.95% less from 1.03 billion shares in 2017Q2 were reported. Toronto Dominion Bank & Trust reported 0.07% of its portfolio in General Motors Company (NYSE:GM). Westwood Gru has 17,665 shares for 0.01% of their portfolio. Kistler owns 366 shares. Proshare Llc invested in 0.08% or 203,983 shares. Horizon Kinetics Limited Co reported 30,150 shares. Fulton Comml Bank Na stated it has 11,057 shares or 0.03% of all its holdings. First Trust Advsrs Ltd Partnership stated it has 834,144 shares or 0.09% of all its holdings. Profund Advsr owns 30,710 shares. Aviance Lc holds 0.28% or 20,227 shares in its portfolio. Hamel accumulated 31,385 shares or 0.62% of the stock. Tower Cap Ltd Liability Co (Trc) reported 0.01% of its portfolio in General Motors Company (NYSE:GM). Lazard Asset Mgmt Ltd Llc invested 0% of its portfolio in General Motors Company (NYSE:GM). Cap Rech Global Invsts invested 0.14% in General Motors Company (NYSE:GM). Zeke Capital Advsrs reported 15,351 shares. Camelot Portfolios Ltd reported 10,455 shares.

Among 8 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Arrowhead Research Corp has $20.0 highest and $2.0 lowest target. $2.92’s average target is -54.23% below currents $6.38 stock price. Arrowhead Research Corp had 20 analyst reports since August 5, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 3 by Jefferies. On Monday, November 27 the stock rating was upgraded by Piper Jaffray to “Buy”. Chardan Capital Markets initiated the shares of ARWR in report on Thursday, May 19 with “Buy” rating. William Blair downgraded the shares of ARWR in report on Wednesday, November 30 to “Mkt Perform” rating. As per Monday, September 18, the company rating was upgraded by William Blair. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Buy” rating given on Thursday, November 10 by Chardan Capital Markets. The stock has “Neutral” rating by Chardan Capital Markets on Wednesday, November 30. The company was downgraded on Wednesday, November 30 by PiperJaffray. As per Thursday, September 14, the company rating was maintained by Piper Jaffray. The company was maintained on Friday, September 25 by Piper Jaffray.

LEAVE A REPLY

Please enter your comment!
Please enter your name here